**Robust IPO activity in October and November 2026 is the dominant factor shaping sentiment on whether any IPOs will occur before 2027.** Multiple companies have priced or scheduled listings recently, including TRex Bio and Retension Pharmaceuticals on Nasdaq in early October, alongside international deals such as Jio Platforms in India and Firmus in Australia. Fresh S-1 and F-1 filings surged in the first week of October, with pipelines heavy in AI infrastructure, data centers, and biotech. Anthropic’s confidential filing and reported November target, plus Blockchain.com’s 2026 plans, underscore ongoing momentum despite selective delays for mega-deals like OpenAI, which shifted to 2027 amid valuation scrutiny and market volatility. Equity market conditions, including sustained risk appetite for growth names, support a busy fourth-quarter window, though high interest rates and investor selectivity on valuations remain key variables.